A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SERENADE
- Sponsors Actelion Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 10 Nov 2017 Planned End Date changed from 28 Mar 2020 to 18 May 2020.
- 10 Nov 2017 Planned primary completion date changed from 28 Mar 2020 to 18 May 2020.